Onglyza

saxagliptin

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Onglyza. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Onglyza.

What is Onglyza?

Onglyza is a medicine that contains the active substance saxagliptin. It is available as tablets (2.5 mg and 5 mg).

What is Onglyza used for?

Onglyza is used in adults who have type-2 diabetes to control their blood glucose (sugar) level. It is used on its own, in addition to diet and exercise, in patients who cannot take metformin and whose glucose levels are not satisfactorily controlled by diet and exercise alone. It is also used in addition to diet and exercise and together with other antidiabetes medicines in the following ways:

  • with metformin in patients whose glucose levels are not satisfactorily controlled on metformin;
  • with a sulphonylurea in patients whose glucose levels are not satisfactorily controlled on sulphonylurea and in whom treatment with metformin is not considered appropriate;
  • with a thiazolidinedione in patients whose glucose levels are not satisfactorily controlled on thiazolidinedione;
  • with insulin (with or without metformin) in patients whose glucose levels are not satisfactorily controlled on insulin (with or without metformin);
  • with metformin and a sulphonylurea in patients whose blood glucose is not adequately controlled by combined metformin and sulphonylurea treatment.

The medicine can only be obtained with a prescription.

How is Onglyza used?

The recommended dose of Onglyza is 5 mg taken once a day, at any time of the day. The dose of Onglyza should be reduced to 2.5 mg once a day in patients with moderate or severe renal problems. If used in combination with insulin or a sulphonylurea the dose of these medicines may need to be lowered, to reduce risk of hypoglycaemia (low blood sugar levels).

How does Onglyza work?

Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. The active substance in Onglyza, saxagliptin, is a dipeptidyl-peptidase-4 (DPP-4) inhibitor. It works by blocking the breakdown of ‘incretin’ hormones in the body. These hormones are released after a meal and stimulate the pancreas to produce insulin. By increasing levels of incretin hormones in the blood, saxagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high. Saxagliptin does not work when the blood glucose is low. Saxagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon. Together, these processes reduce blood glucose levels and help to control type-2 diabetes.

How has Onglyza been studied?

Onglyza was investigated in ten main studies involving over 5,000 adults with type-2 diabetes.

Four studies involving a total of 2,531 patients looked at Onglyza when added to metformin, a thiazolidinedione, a sulphonylurea, or insulin with or without metformin, comparing its effect to that of placebo (a dummy treatment). A fifth study in 257 patients compared Onglyza with placebo when added to metformin and a sulphonylurea.

Five additional studies looked at Onglya given on its own, with four studies comparing Onglyza with placebo and another comparing Onglyza with metformin in patients who had not previously received substantial treatment with antidiabetes medicines.

The main measure of effectiveness was the change in the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled. HbA1c levels were measured after 24 weeks.

What benefit has Onglyza shown during the studies?

Onglyza was more effective than placebo at controlling blood glucose, when used as an ‘add-on’ in patients in whom previous treatment had failed.

In patients who took Onglyza in addition to metformin, HbA1c levels had fallen by around 0.7% after 24 weeks (from around 8.1% to around 7.4%) compared with an increase of around 0.1% in patients taking placebo. For patients who took Onglyza with a sulphonylurea and a thiazolidinedione, HbA1c levels fell by around 0.6% and 0.9%, respectively, compared with an increase of around 0.1% and a decrease of around 0.3%, respectively, in patients who took placebo. For patients who took Onglyza in addition to insulin (with or without metformin), HbA1c levels fell by around 0.7%, compared with a decrease of around 0.3% in patients who took placebo. For patients who took Onglyza with metformin and a sulphonylurea, a reduction in HbA1c levels of 0.7% was seen, compared with a reduction of 0.1% in patients who were given placebo in place of Onglyza.

The studies with Onglyza on its own showed that, on average, in patients given Onglyza HbA1c levels fell by around 0.5% more than in patients given placebo.

The results of study with Onglyza plus metformin in patients who had not previously received substantial treatment with antidiabetes medicines were not considered to be clinically relevant and the company withdrew its application for the use of Onglyza as an initial combination medicine in previously untreated patients.

What is the risk associated with Onglyza?

The most common side effects with Onglyza (seen in between 1 and 10 patients in 100) are upper-respiratory-tract infection (colds), urinary-tract infection (infection of the structures that carry urine), gastroenteritis (inflammation of the stomach and gut), sinusitis (inflammation of the sinuses), headache, vomiting and mild to moderate peripheral oedema (swelling, especially of the ankles and feet) in patients taking Onglyza with a thiazolidinedione. For the full list of all side effects reported with Onglyza, see the package leaflet.

Onglyza must not be used in people who are hypersensitive (allergic) to saxagliptin, any of the other ingredients or who have ever had a serious allergic reaction to any DPP-4 inhibitor.

Why has Onglyza been approved?

The CHMP decided that Onglyza’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Other information about Onglyza

The European Commission granted a marketing authorisation valid throughout the European Union for Onglyza on 1 October 2009.

For more information about treatment with Onglyza, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Onglyza : EPAR - Summary for the public BG = bălgarski 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public ES = español 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public CS = čeština 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public DA = dansk 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public DE = Deutsch 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public ET = eesti keel 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public EL = elliniká 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public EN = English 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public FR = français 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public IT = italiano 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public LV = latviešu valoda 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public LT = lietuvių kalba 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public HU = magyar 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public MT = Malti 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public NL = Nederlands 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public PL = polski 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public PT = português 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public RO = română 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public SK = slovenčina 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public SL = slovenščina 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public FI = suomi 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public SV = svenska 27/10/2009 27/09/2013
Onglyza : EPAR - Summary for the public HR = Hrvatski 27/10/2009 27/09/2013

This EPAR was last updated on 23/11/2015 .

Authorisation details

Product details

Product details for Onglyza
NameOnglyza
Agency product numberEMEA/H/C/001039
Active substance

saxagliptin

International non-proprietary name (INN) or common name

saxagliptin

Therapeutic area Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code A10BH03

Publication details

Publication details for Onglyza
Marketing-authorisation holder

AstraZeneca AB

Revision13
Date of issue of marketing authorisation valid throughout the European Union01/10/2009

Contact address:

AstraZeneca AB
151 85 Södertälje
Sweden

Product information

Product information

01/10/2015  Onglyza -EMEA/H/C/001039 -WS/0810/G

Name Language First published Last updated
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015
Onglyza : EPAR - Product Information HR = Hrvatski 27/10/2009 23/11/2015

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011
Onglyza : EPAR - All Authorised presentations HR = Hrvatski 27/10/2009 29/03/2011

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Add-on combination therapy

Onglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:

as monotherapy:

  • in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;

as dual oral therapy:

  • in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;
  • in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;
  • in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;

as triple oral therapy:

  • in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;

as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Assessment History

Changes since initial authorisation of medicine

Initial marketing-authorisation documents

Name Language First published Last updated
Onglyza : EPAR - Public assessment report HR = Hrvatski 27/10/2009  
Committee for medicinal products for human use, summary of positive opinion for Onglyza HR = Hrvatski 25/06/2009